• Journal of Ginseng Research
• /
• 제28권2호
• /
• pp.104-110
• /
• 2004

본 연구는 근치적 위절제 및 림프절 절제와 혹은 절제불가능 환자에서 항암화학요법 치료를 받는 위암환자에서 홍삼액기스 투여군에서 비록 각군의 대상 개체의 표본수가 적음에도 불구하고 홍삼엑기스 투여군에서 항암 cytokine으로 알려진 IL-2가 위암 대조군에 비하여 높게 나타나고 숙주의 항암 면역기능을 저해하는 cytokine인 IL-10은 수술 후 1개월에 홍삼엑기스 투여군에서 위암 대조군에 보다 그 감소비가 높게 나타났으며, 수술 후 3개월에는 홍삼엑기스 투여군에서만 건강 대조군 값에 접근하는 결과를 보여 보조 항암 화학요법 기간에서 홍삼엑기스의 투여는 위암 환자에서의 숙주의 항암 면역 억제의 현상을 빠른 시간 내에 회복시킬 수 있는 효과가 있는 것으로 보여진다. 대단위 개체를 포함하는 지속적인 추가 연구의 필요성이 절실하며 이러한 추가 연구가 진행 된다면 홍삼엑기스의 위암환자에서의 항암 면역기능의 역할을 임상적으로 증명 할 수 있으리라고 기대 된다.

• 대한두경부종양학회지
• /
• 제28권2호
• /
• pp.125-128
• /
• 2012

Salivary duct carcinoma(SDC) is a highly malignant tumor of the salivary gland. The tumor is clinically characterized by a rapid onset and progression, the neoplasm is often associated with pain and facial paralysis. The nodal recurrence rate is high, and distant metastasis is common. SDC resembles high-grade breast ductal carcinoma. Curative surgical resection and postoperative radiation were the mainstay of the treatment. If facial paralysis is present, a radical parotidectomy is mandatory. Regardless of the primary location of SDC, ipsilateral functional neck dissection is indicated, because regional lymphatic spread has to be expected in the majority of patients already at time of diagnosis. If there is minor gland involvement, a bilateral neck dissection should be performed, because lymphatic drainage may occur to the contralateral side. The survival of SDC patient is poor, with most dying within three years. We experienced a unique case of SDC in parotid deep lobe. We report the clinicopathologic features of this tumor with a review of literature.

• Archives of Plastic Surgery
• /
• 제37권5호
• /
• pp.702-704
• /
• 2010

Purpose: Chordoma is a rare primary osseous tumor arising from the remnants of the primitive notochord. It occurs once in 2,000,000. It is characterized by its slow growth, high frequency to invade destroy bone by direct extension. We experienced giant sacral chordoma and reconstructed with gluteal advancement flap. Methods: A 52-year-old woman presented with a 2-years history of gluteal pain. In the biopsy study revealed sacral chordoma. MRI study showed $13{\times}12{\times}10\;cm$ sized m0cs. We approached anterior and posterior resection and reconstructed with bilateral gluteus maximus advancement flap. Results: After the operation, blader and anal function were slightly decreased. But, 4 months later those were almost fully recovered. There was no significant complication and recurrence after 2-years follow-up. Conclusion: Chordoma is characterized by its slow growth, high frequency to invade and destroy bone by direct extension. Wide surgical resection is the only curative procedure. We report a ase of giant sacral chordoma which was successfully treated by anterior and posterior approach and reconstructed with bilateral gluteal advancement flap.

• Journal of Chest Surgery
• /
• 제12권1호
• /
• pp.16-22
• /
• 1979

Clinical evaluation of contact sensitization to 2, 4-dinitro-chlorobenzene [DNCB] was performed in 2 groups: group A [30 patients with non-malignant disease] and group B [30 patients with bronchogenic carcinoma]. Initial sensitization was elicited out by applying 2, 000 ug of DNCB to skin surface of the both group A and B. Subsequently a relatively weak challenge dose, 200 ug of DNCB, was applied 14 days later, showing the satisfactory results of sensitization with minimizing non-specific irritative inflammatory skin response. Delayed cutaneous hypersensitivity reactions shown by spontaneous flare phenomena appeared at the challenge site, and they were assessed 48 hours later. The reaction were graded from +1 to +4 according to the degree of flare or vesicular reaction. The results were as follows: 1. 28 cases [93%] of group A, however, only 18 cases [67%] of group B exhibited delayed cutaneous hypersensitivity reaction to DNCB contact sensitization [P<0.02]. 2. Of group A, the delayed cutaneous hypersensitivity reactions above +2 of DNCB score were 25 cases [83%], meanwhile 11 cases [37%] in group B [P<0.001]. 3. Undifferentiated carcinomas showed highest incidence of anergy to DNCB contact sensitization in the all histologic types of group B. 4. In group B, 8 [42%] of 19 cases who react to DNCB were resectable, whereas only 2 [18 %] of 11 cases who failed to react to DNCB were resectable for curative cancer surgery. These study suggests that cellular immune reaction of group B was depressed remarkably comparing with that of group A.

• Journal of Chest Surgery
• /
• 제35권10호
• /
• pp.724-729
• /
• 2002

지금까지 수부 다한증에 대한 다양한 교감신경 수술방법들은 확실하고 안전한 치료방법이기는 하지만 술후 보상성 발한의 발생과 더불어 수장부의 무한증을 유발시킴으로써 장기적인 환자만족도를 떨어뜨리는 것이 문제가 되어왔다. 대상 및 방법: 이에 본 교실에서는 손에 분포하는 교감신경절 교통가지를 선택적으로 절제함으로써 술후 보상성 발한의 정도를 감소시키고 수장부의 무한증을 예방하고자 하였다. 결과: 수술 결과 절반 이상의 환자에서 손에 적당히 촉촉함을 유지할 수 있었으며 동시에 보상성 발한에 있어서도 대부분의 환자에서 생활에 불편을 초래하지 않는 정도의 경등도 이하로 나타났다. 결론: 교감신경절 교통가지 절제술은 수장부 다한증에 대한 보다 선택적이고 생리적인 수술방법으로 생각된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권6호
• /
• pp.2151-2159
• /
• 2015

Pancreatic neuroendocrine tumors (pNETs) are rare and heterogenous tumors and surgery to remove the primary tumor is the mainstay of treatment for resectable disease. However, curative surgery is often not feasible, because half of patients with pNET have metastases at the time of diagnosis. Palliative dubulking surgery and liver-directed therapies are appropriate options for these patients. Streptozocin-based regimens are standard, although temozolamide-based treatments are rapidly gaining wide clinical application. Somatostatin analogs are mainly indicated in hormonally active tumors to ameliorate symptoms. In addition, anti-tumoral activity has been proven in well-differentiated NETs. Recently, there has been tremendous progress in the molecular biology of pNETs; thereby, the efficacy of sunitinib and everolimus in the treatment of patients with metastatic pNETs has been proven by large placebo-controlled phase III trials. Currently, there are no definitively proven predictive biomarkers to evaluate response to medical therapies in patients with pNET. Therefore, further studies are needed to individualize and optimize their management. This article reviews systemic chemotherapy, targeted therapies, and anti-secretory treatments for the management of patients with unresectable or metastatic pNETs, summarized in the light of recent advances.

• Journal of Gastric Cancer
• /
• 제18권2호
• /
• pp.152-160
• /
• 2018

Purpose: Totally laparoscopic gastrectomy (TLG) for advanced gastric cancer (AGC) is a technically and oncologically challenging procedure for surgeons. This study aimed to compare the oncologic feasibility and technical safety of TLG for AGC versus early gastric cancer (EGC). Materials and Methods: Between 2011 and 2016, 535 patients (EGC, 375; AGC, 160) underwent curative TLG for gastric cancer. Clinicopathologic characteristics and surgical outcomes of both patient groups were analyzed and compared. Results: Patients with AGC required a longer operation time and experienced more intraoperative blood loss than those with EGC did. However, patients from both the AGC and EGC groups demonstrated similar short-term surgical outcomes such as postoperative morbidity (14.4% vs. 13.3%, P=0.626), mortality (0% vs. 0.5%, P=0.879), time-to-first oral intake (2.7 days for both groups, P=0.830), and postoperative hospital stay (10.2 days vs. 10.1 days, P=0.886). D2 lymph node dissection could be achieved in the AGC group (95%), with an adequate number of lymph nodes being dissected ($36.0{\pm}14.9$). In the AGC group, the 3-year overall and disease-free survival rates were 80.5% and 73.7%, respectively. Conclusions: TLG is as safe and effective for AGC as it is for EGC.

• Journal of Gastric Cancer
• /
• 제21권3호
• /
• pp.236-245
• /
• 2021

Purpose: The numeric N stage has replaced the topographic N stage in the current tumor node metastasis (TNM) staging in gastric carcinoma. However, the usefulness of the topographic N stage in the current TNM staging system is uncertain. We aimed to investigate the prognostic value of the topographic N stage in the current TNM staging system. Materials and Methods: We reviewed the data of 3350 patients with gastric cancer who underwent curative gastrectomy. The anatomic regions of the metastatic lymph nodes (MLNs) were classified into 2 groups: perigastric and extra-perigastric. The prognostic value of the anatomic region was analyzed using a multivariate prognostic model with adjustments for the TNM stage. Results: In patients with lymph node metastasis, extra-perigastric metastasis demonstrated significantly worse survival than perigastric metastasis alone (5-year survival rate, 39.6% vs. 73.1%, respectively, P<0.001). Extra-perigastric metastasis demonstrated significantly worse survival within the same pN stage; the multivariate analysis indicated that extra-perigastric metastasis was an independent poor prognostic factor (hazard ratio=1.33; 95% confidence interval=1.01-1.75). The anatomic region of the MLNs improved the goodness-of-fit (likelihood ratio statistics, 4.57; P=0.033) of the prognostic model using the TNM stage. Conclusions: The anatomic region of MLNs has an independent prognostic value in the numeric N stage in the current TNM staging of gastric carcinoma.

• Journal of Digestive Cancer Research
• /
• 제3권1호
• /
• pp.17-20
• /
• 2015

췌장암은 예후가 좋지 않은 악성 질환으로 진단 당시 10-20%에서만 수술적 절제가 가능한 것으로 알려져 있다. 수술적 절제가 유일한 근치적 치료로 알려져 있으나, 높은 재발률로 인해 예후가 좋지 않아 예후를 개선시키기 위한 항암화학요법이나 방사선요법 등의 보조적 치료가 시도되고 있다. 수술 후 보조항암요법이 시행되고 있으나 생존율의 향상은 미비한 수준으로 최근에는 항암화학요법, 항암방사선요법, 항암화학요법 후 항암방사선요법 등의 다양한 선행보조항암요법이 시행되고 있다. 본 종설에서는 절제 가능한 췌장암과 국소진행성 췌장암에서의 선행보조항암요법에 대한 최근의 연구를 정리하고 임상적인 역할에 대해 규명해 보고자 한다.

• Journal of Gastric Cancer
• /
• 제12권4호
• /
• pp.217-222
• /
• 2012

Purpose: We conducted this study to study the clinical correlation between the characteristics of gastric cancer and serum selenium and zinc levels. Materials and Methods: The following data were measured in the baseline serum selenium and zinc levels of 74 patients with curative gastrectomy subsequent to confirmed gastric cancer, from March 2005 to August 2012. Results: Among the 74 gastric cancer patients, 53 patients were male. Mean serum selenium and zinc levels were $118.7{\pm}33.1$ ug/L and $72.2{\pm}24.3$ ug/dl, respectively. Seven patients (9.5%) showed lower selenium level, and 33 patients (44.6%) showed lower zinc level. Serum Selenium level was $99.1{\pm}31.8$ ug/L in cardia cancer group (10 cases) and $121.8{\pm}32.4$ ug/L in non-cardia cancer group (64 cases)(P=0.044). According to tumor gross type, zinc level was $78.7{\pm}29.6$ ug/dl in early gastric cancer (33) and $66.9{\pm}17.8$ ug/dl in advanced gastric cancer (41) (P=0.064). Conclusions: The serum selenium level was highly correlated with the location of gastric cancer. The serum zinc level was lower in advanced gastric cancer.